HF4412

Purpose

Clarify and expand Minnesota’s medical cannabis program by adding new endorsements for different parts of the supply chain, tightening how medical cannabis is distributed to patients, and strengthening the role of licensed professionals in determining appropriate products and dosages.

Main Provisions

• Endorsement framework for cannabis businesses

  • The office may issue a medical cannabis endorsement to allow a business to work with medical cannabis in specific ways, including cultivation, processing, and retail (selling or distributing) to people enrolled in the medical cannabis program.
  • Cultivation endorsement: Allows a license holder to grow cannabis plants, harvest flowers, and sell or transfer cannabis flower to other cannabis businesses with medical cannabis endorsements. Plants must be grown within an approved space and follow office rules.
  • Processor endorsement: Allows a license holder to purchase medical cannabis flower, hemp plant parts, or hemp concentrate; make cannabis concentrate (including hemp concentrate that has delta-9 THC above 0.3% by weight); manufacture medical cannabinoid products; package/label products for sale to other medical cannabis businesses; and perform other office-approved actions.
  • Retail endorsement: Allows a license holder to buy medical cannabis flower and medical cannabinoid products from cultivator or processor endorsements and sell or distribute them to patients or others enrolled in the program. Requires at least one employee who has a medical cannabis consultant certificate or a licensed pharmacist to provide final authorization, or to employ/contract with a licensed pharmacist to consult for patient enrollment in the registry.
  • Testing and safety requirement: The retail endorsement requires verification that medical cannabis products have passed safety potency and consistency testing at an office-approved testing facility before distribution to patients.

• Distribution and patient-verification requirements

  • Before distributing medical cannabis flower or medical cannabinoid products to a person enrolled in the registry, staff must verify the patient’s enrollment, confirm the patient or their designated caregiver/parent/legal guardian/spouse, and confirm the patient had a consultation with a medical cannabis consultant (certificate issued by the office) or a licensed pharmacist to determine proper dosage and usage.
  • Each distribution must carry a patient-specific label with dosage recommendations and other required information, and staff must provide any other info required by the office.
  • A retailer with a medical cannabis retail endorsement may not deliver medical cannabis unless the business also holds a cannabis delivery service license.
  • Delivery and distribution are subject to existing rules about how cannabis is delivered (with safety and regulatory oversight).

• Final approval and professional oversight

  • Final approval for distribution must be given by a licensed pharmacist (under chapter 151) or by a certified medical cannabis consultant (certificate issued by the office) who has consulted with the patient to determine the appropriate product and dosage after reviewing the product’s chemical composition.
  • The consultation covers:
  • First-time purchases
  • Changes in administration method
  • Increases in dosage (e.g., a product with at least double the prior dosage)
  • Remote consultations are allowed via secure videoconference, telephone, or other remote means, as long as the patient’s identity and privacy are protected.

Significant Changes to Existing Law

• New endorsement categories
  • Adds explicit cultivation, processor, and retailer endorsements to the medical cannabis program, expanding what licensed businesses can do within the program.
• Expanded product and process capabilities
  • Allows processing of hemp concentrate and higher-THC hemp products, broadening manufacturing options for medical cannabinoid products.
• Strengthened distribution controls
  • Introduces more stringent pre-distribution checks, patient verification, and patient-specific dosage labeling to improve safety and accountability.
• Increased professional involvement
  • Elevates the role of licensed pharmacists and certified medical cannabis consultants in determining proper products and dosages, including final approval for distribution, with remote options for consultations.
• Telemedicine and remote access
  • Explicitly permits remote consultations to meet patient needs while protecting privacy.

Potential Impacts (what this could mean)

• Patient safety and dosing
  • More precise dosing guidance and professional oversight may improve patient outcomes and reduce misuse or errors.
• Access and logistics
  • Requiring certain endorsements and delivery licensing could affect how quickly some patients can access products and may increase compliance costs for licensees.
• Regulatory clarity
  • Clear rules for testing, labeling, and final approval help align industry practices with state requirements and patient protections.
• Industry structure
  • The new endorsement framework may encourage collaboration among cultivators, processors, and retailers, and creates defined pathways for expanding medical cannabis services.

Relevant Terms - medical cannabis endorsement - cultivation endorsement - processor endorsement - retailer endorsement - medical cannabis registry program - medical cannabis consultant - licensed pharmacist (chapter 151) - delta-9 tetrahydrocannabinol (delta-9 THC) - hemp concentrate - hemp plant parts - medical cannabinoid products - safety potency and consistency testing - cannabis testing facility - patient enrollment - designated caregiver - secure videoconference - telemedicine - delivery service license - final approval - office (Minnesota Office)